Infinity Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 32 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-05-25: Reporting owner SELBY NORMAN C; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-05-25: Reporting owner SELBY NORMAN C; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-05-25: Reporting owner SELBY NORMAN C; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-05-25: Reporting owner BLOCH LAWRENCE E; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-05-25 | SELBY NORMAN C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | SELBY NORMAN C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | SELBY NORMAN C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +2,000 2,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | BLOCH LAWRENCE E Officer (President) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 250,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | Berkowitz Jeffrey Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | EVNIN ANTHONY B Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | EVNIN ANTHONY B Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +2,000 2,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | SMITH IAN F Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | SMITH IAN F Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,000 4,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | Kutok Jeffery Officer (Chief Scientific Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +125,000 125,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | VENUTI MICHAEL C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | VENUTI MICHAEL C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,000 4,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-05-25 | Tasker Seth A Officer (General Counsel) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $1.74 exercise price | 2017-05-26 | |
| 2017-04-05 | Kauffman Michael Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $2.80 exercise price | 2017-04-06 | |
| 2017-02-14 holding as of filing | Kutok Jeffery Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.94 exercise price | 2017-02-14 | ||
| 2017-02-14 holding as of filing | Kutok Jeffery Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $7.93 exercise price | 2017-02-14 | ||
| 2017-02-14 holding as of filing | Kutok Jeffery Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $8.12 exercise price | 2017-02-14 | ||
| 2017-02-14 holding as of filing | Kutok Jeffery Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $36.85 exercise price | 2017-02-14 | ||
| 2017-02-14 holding as of filing | Kutok Jeffery Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $22.55 exercise price | 2017-02-14 | ||
| 2017-02-14 holding as of filing | Kutok Jeffery Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $12.91 exercise price | 2017-02-14 | ||
| 2017-02-14 holding as of filing | Kutok Jeffery Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $15.74 exercise price | 2017-02-14 | ||
| 2017-02-14 holding as of filing | Kutok Jeffery Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.71 exercise price | 2017-02-14 | ||
| 2017-02-10 | Kutok Jeffery Officer (Chief Scientific Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 250,000 owned after | $2.45 exercise price | 2017-02-14 | |
| 2017-01-06 | VENUTI MICHAEL C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.46 exercise price | 2017-01-09 | |
| 2017-01-06 | EVNIN ANTHONY B Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.46 exercise price | 2017-01-09 | |
| 2017-01-06 | SMITH IAN F Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.46 exercise price | 2017-01-09 | |
| 2017-01-06 | SELBY NORMAN C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.46 exercise price | 2017-01-09 | |
| 2017-01-06 | Perkins Adelene Q Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,000,000 1,000,000 owned after | $1.46 exercise price | 2017-01-09 | |
| 2017-01-06 | Baselga Jose Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.46 exercise price | 2017-01-09 | |
| 2017-01-06 | BLOCH LAWRENCE E Officer (President) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +500,000 500,000 owned after | $1.46 exercise price | 2017-01-09 | |
| 2017-01-06 | Tasker Seth A Officer (General Counsel) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 250,000 owned after | $1.46 exercise price | 2017-01-09 | |
| 2017-01-06 | Berkowitz Jeffrey Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.46 exercise price | 2017-01-09 |